马来酸曲美布汀联合枯草杆菌二联活菌肠溶胶囊对肠易激综合征的疗效及对白细胞介素—6的影响(1)
【摘要】 目的：观察马来酸曲美布汀联合枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征的临床疗效，并观察患者血清白细胞介素-6(IL-6)水平变化情况。方法：选取本院消化内科门诊及住院部肠易激综合征患者144例，按照入院顺序编号，分为治疗组与对照组，每组各72例。对照组口服枯草杆菌二联活菌肠溶胶囊500 mg，3次/d；治疗组则在对照组的基础上口服马来酸曲美布汀0.1 g，3次/d，治疗周期为60 d，比较两组的临床疗效及IL-6水平的影响。结果：治疗组的总有效率为97.22%，对照组为83.33%，治疗组总有效率明显高于对照组，两组比较差异有统计学意义(P<0.05)。两组治疗前的IL-6水平比较差异无统计学意义(P>0.05)，两组治疗后的IL-6水平均有不同程度的降低，治疗前后比较差异有统计学意义(P<0.05)；治疗组降低程度明显大于对照组，两组比较差异有统计学意义(P<0.01)。两组均未见明显的药物不良反应，治疗组有2例患者在首次服用药物出现轻微恶心、口渴的症状，均自行缓解，后未见发生；对照组未见明显不良反应。结论：马来酸曲美布汀联合枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征有不错的临床疗效，并且对血清IL-6的含量亦有着明显调节作用。
, http://www.100md.com
【关键词】 马来酸曲美布汀； 枯草杆菌二联活菌肠溶胶囊； 肠易激综合征； 血清白细胞介素-6
【Abstract】 Objective：To observe the clinical efficacy of Trimebutine Maleate combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules in the treatment of irritable bowel syndrome(IBS)，and to observe the change of serum interleukin-6(IL-6) level.Method：144 patients with irritable bowel syndrome in gastroenterology department outpatient and inpatient of our hospital were selected，according to the order of admission number，they were divided into the treatment group and the control group，72 cases in each group.The control group was given oral Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules 500 mg，3 times a day.On the basis of the control group，the treatment group was treated with Trimebutine Maleate 0.1 g，3 times a day.Treatment period for 60 days，the clinical curative effect and the IL-6 level between the two groups were compared.Result：The total effective rate of the treatment group was 97.22%，which was significantly higher than 83.33% of the control group，the difference was statistically significant(P<0.05).Before treatment，the difference was not statistically significant in IL-6 level between the two groups(P>0.05).After treatment，the IL-6 level of two groups were significantly lower than before treatment and the decreased degree of the treatment group was significantly higher than the control group，the differences were statistically significant(P<0.05).There were no obvious adverse reactions in two groups，there were 2 patients with mild nausea and thirst for the first time in the treatment group，and the symptoms were relieved，no obvious adverse reactions were found in the control group.Conclusion：Trimebutine Maleate combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules in the treatment of irritable bowel syndrome (IBS)has a good clinical efficacy and serum IL-6 content also has a significant regulatory role., 百拇医药(顾秋平 刘金金)
, http://www.100md.com
【关键词】 马来酸曲美布汀； 枯草杆菌二联活菌肠溶胶囊； 肠易激综合征； 血清白细胞介素-6
【Abstract】 Objective：To observe the clinical efficacy of Trimebutine Maleate combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules in the treatment of irritable bowel syndrome(IBS)，and to observe the change of serum interleukin-6(IL-6) level.Method：144 patients with irritable bowel syndrome in gastroenterology department outpatient and inpatient of our hospital were selected，according to the order of admission number，they were divided into the treatment group and the control group，72 cases in each group.The control group was given oral Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules 500 mg，3 times a day.On the basis of the control group，the treatment group was treated with Trimebutine Maleate 0.1 g，3 times a day.Treatment period for 60 days，the clinical curative effect and the IL-6 level between the two groups were compared.Result：The total effective rate of the treatment group was 97.22%，which was significantly higher than 83.33% of the control group，the difference was statistically significant(P<0.05).Before treatment，the difference was not statistically significant in IL-6 level between the two groups(P>0.05).After treatment，the IL-6 level of two groups were significantly lower than before treatment and the decreased degree of the treatment group was significantly higher than the control group，the differences were statistically significant(P<0.05).There were no obvious adverse reactions in two groups，there were 2 patients with mild nausea and thirst for the first time in the treatment group，and the symptoms were relieved，no obvious adverse reactions were found in the control group.Conclusion：Trimebutine Maleate combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules in the treatment of irritable bowel syndrome (IBS)has a good clinical efficacy and serum IL-6 content also has a significant regulatory role., 百拇医药(顾秋平 刘金金)